Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2024

29-10-2023 | Pancreatic Cancer | Pancreatic Tumors

Prevalence and Impact of Frailty in Pancreatic Cancer: A Systematic Review and Meta-Analysis Based on 35,191 Patients

Authors: Fei Zhang, MD, MPH, Ying Yan, BN, Chunlin Ge, MD

Published in: Annals of Surgical Oncology | Issue 1/2024

Login to get access

Abstract

Background

Frailty has been associated with increased mortality among patients with pancreatic cancer. Nevertheless, several lines of evidence regarding the prevalence of frailty in patients with pancreatic cancer and mortality in patients with pancreatic cancer and frailty have not been thoroughly investigated and require clarification.

Methods

A systematic review and meta-analysis of studies indexed in PubMed, Scopus, Web of Science, and Embase through March 2023 were conducted, and the pooled prevalence and relative risk (RR) estimate were calculated.

Results

A total of 18 studies containing 35,191 patients with pancreatic cancer were included. The prevalence of frailty in pancreatic cancer was 45% (95% CI = 29–62; I2 = 99.9%; p = 0.000). In patients with pancreatic cancer, frailty was associated with increased relative risk for mortality (RR = 1.70; 95% CI = 1.30–2.22; I2 = 84.8%, p = 0.000).

Conclusions

Frailty prevalence in pancreatic cancer is common and exerts a significant negative impact on the survival of patients with pancreatic cancer. Our findings are characterized by significant heterogeneity, and caution is warranted in their interpretation. However, these findings highlight the importance of evaluating frailty, which may provide prognostic data and inform decision-making priorities.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.CrossRefPubMed
2.
Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology. 2021;160(3):744–754.PubMedCrossRef
3.
4.
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–502.PubMedPubMedCentralCrossRef
5.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–762.PubMedCrossRef
6.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-156.PubMedCrossRef
7.
Komici K, Cappuccio M, Scacchi A, et al. The prevalence and the impact of frailty in hepato-biliary pancreatic cancers: A systematic review and meta-analysis. J Clin Med. 2022;11(4).
8.
Veronese N, Custodero C, Cella A, et al. Prevalence of multidimensional frailty and pre-frailty in older people in different settings: a systematic review and meta-analysis. Ageing Res Rev. 2021;72:101498.PubMedCrossRef
9.
Houghton JSM, Nickinson ATO, Morton AJ, et al. Frailty factors and outcomes in vascular surgery patients: a systematic review and meta-analysis. Ann Surg. 2020;272(2):266–276.PubMedCrossRef
10.
Kochar A, Deo SV, Charest B, et al. Preoperative frailty and adverse outcomes following coronary artery bypass grafting surgery in US veterans. J Am Geriatr Soc. 2023;71(9):2736–2747.PubMedCrossRef
11.
Hewitt J, Long S, Carter B, Bach S, McCarthy K, Clegg A. The prevalence of frailty and its association with clinical outcomes in general surgery: a systematic review and meta-analysis. Age Ageing. 2018;47(6):793–800.PubMedCrossRef
12.
Augustin T, Burstein MD, Schneider EB, et al. Frailty predicts risk of life-threatening complications and mortality after pancreatic resections. Surgery. 2016;160(4):987–996.PubMedCrossRef
13.
Rostoft S, van Leeuwen B. Frailty assessment tools and geriatric assessment in older patients with hepatobiliary and pancreatic malignancies. Eur J Surg Oncol. 2021;47(3 Pt A):514–518.
14.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLos Med. 2009;339:b2700.
15.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2014;12(12):1495–1499.
16.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.PubMedCrossRef
17.
Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(Pt 1):97–128.PubMedCrossRef
18.
Benjamin AJ, Buschmann MM, Schneider A, et al. Can comprehensive imaging analysis with analytic morphomics and geriatric assessment predict serious complications in patients undergoing pancreatic surgery? J Gastrointest Sur. 2017;21(6):1009–1016.CrossRef
19.
Mogal H, Vermilion SA, Dodson R, et al. Modified frailty index predicts morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol. 2017;24(6):1714–1721.PubMedPubMedCentralCrossRef
20.
Ngo-Huang A, Holmes HM, des Bordes JKA, et al. Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Cancer Med. 2019;8(6): 2867–2876.
21.
Nakano Y, Hirata Y, Shimogawara T, et al. Frailty is a useful predictive marker of postoperative complications after pancreaticoduodenectomy. World J Surg Oncol. 2020;18(1):194.PubMedPubMedCentralCrossRef
22.
Al Abbas AI, Borrebach JD, Pitt HA, et al. Development of a novel pancreatoduodenectomy-specific risk calculator: An analysis of 10,000 patients. J Gastrointest Surg. 2021;25(6):1503–1511.PubMedCrossRef
23.
Gebbia V, Mare M, Cordio S, et al. Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma? J Geriatr Oncol. 2021;12(1):163–167.PubMedCrossRef
24.
Mima K, Hayashi H, Nakagawa S, et al. Frailty is associated with poor prognosis after resection for pancreatic cancer. Int J Clin Oncol. 2021;26(10):1938–1946.PubMedCrossRef
25.
Rieser CJ, Zenati M, Narayanan S, et al. Optimal management of resectable pancreatic head cancer in the elderly patient: does neoadjuvant therapy offer a survival benefit? Ann Surg Oncol. 2021;28(11):6264–6272.PubMedPubMedCentralCrossRef
26.
Rittberg R, Zhang H, Lambert P, Kudlovich R, Kim CA, Dawe DE. Utility of the modified frailty index in predicting toxicity and cancer outcomes for older adults with advanced pancreatic cancer receiving first-line palliative chemotherapy. J Geriatr Oncol. 2021;12(1):112–117.PubMedCrossRef
27.
Yamada S, Shimada M, Morine Y, et al. Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma. World J Surg Oncol. 2021;19(1):94.PubMedPubMedCentralCrossRef
28.
Kadokura M, Mori Y, Takenaka Y, et al. Usefulness of the G8 geriatric assessment tool as a prognostic factor in gemcitabine plus nab-paclitaxel combination therapy for elderly patients with pancreatic cancer. JMA J. 2022;5(4):512–519.PubMedPubMedCentralCrossRef
29.
Kobayashi S, Suzuki M, Ueno M, et al. Comparing the efficacy and safety of gemcitabine plus nab-paclitaxel versus gemcitabine alone in older adults with unresectable pancreatic cancer. Oncologist. 2022;27(10):e774–e782.PubMedPubMedCentralCrossRef
30.
Li V, Awan A, Serrano PE. Frailty predicts postoperative complications following pancreaticoduodenectomy. Eur Surg Res. 2022;63(4):232–240.PubMedCrossRef
31.
Lund CM, Mikkelsen MK, Theile S, et al. Age-related differences in recall of information and handling of chemotherapy-related side effects in cancer patients: the recap study. Oncologist. 2022;27(2):e185–e193.PubMedPubMedCentralCrossRef
32.
Negrete-Najar JP, Sehovic M, Rodriquenz MG, Garcia-Martinez J, Extermann M. Development of a health data derived frailty index as a predictor of adverse outcomes in older patients with pancreatic cancer. J Geriatr Oncol. 2022;13(3):308–314.PubMedCrossRef
33.
Paiella S, De Pastena M, Esposito A, et al. Modified frailty index to assess risk in elderly patients undergoing distal pancreatectomy: a retrospective single-center study. World J Surg. 2022;46(4):891–900.PubMedPubMedCentralCrossRef
34.
Scholer AJ, Marcus R, Garland-Kledzik M, et al. Validating biologic age in selecting elderly patients with pancreatic cancer for surgical resection. J Surg Oncol. 2023;127(3):394–404.PubMedCrossRef
35.
Dent E, Martin FC, Bergman H, Woo J, Romero-Ortuno R, Walston JD. Management of frailty: opportunities, challenges, and future directions. Lancet. 2019;394(10206):1376–1386.PubMedCrossRef
36.
Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394(10206):1365–1375.PubMedCrossRef
37.
Kong LN, Lyu Q, Yao HY, Yang L, Chen SZ. The prevalence of frailty among community-dwelling older adults with diabetes: A meta-analysis. Int J Nurs Stud. 2021;119:103952.PubMedCrossRef
38.
Li G, Prior JC, Leslie WD, et al. Frailty and risk of fractures in patients with type 2 diabetes. Diabetes Care. 2019;42(4):507–513.PubMedCrossRef
39.
Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124(7):1045–1060.PubMedCrossRef
40.
41.
Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. 2017;236:283–289.PubMedPubMedCentralCrossRef
42.
Pandey A, Kitzman D, Reeves G. Frailty is intertwined with heart failure: mechanisms, prevalence, prognosis, assessment, and management. JACC Heart Fail. 2019;7(12):1001–1011.PubMedPubMedCentralCrossRef
43.
Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224–237.PubMedCrossRef
44.
Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015;26(6):1091–1101.PubMedCrossRef
45.
Wang S, Yang T, Qiang W, et al. The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis. Support Care Cancer. 2022;30(4):2993–3006.PubMedCrossRef
46.
Komici K, Bencivenga L, Navani N, et al. Frailty in patients with lung cancer: a systematic review and meta-analysis. Chest. 2022;162(2):485–497.PubMedCrossRef
47.
48.
Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: the potential role of an aged immune system. Ageing Res Rev. 2017;36:1–10.PubMedCrossRef
49.
Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019;20(3).
50.
Subramaniam S, Aalberg JJ, Soriano RP, Divino CM. New 5-factor modified frailty index using american college of surgeons NSQIP data. J Am Coll Surg. 2018;226(2):173–181.e178.PubMedCrossRef
51.
Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13(10):e437–444.PubMedCrossRef
52.
Meldon SW, Mion LC, Palmer RM, et al. A brief risk-stratification tool to predict repeat emergency department visits and hospitalizations in older patients discharged from the emergency department. Acad Emerg Med. 2003;10(3):224–232.PubMed
53.
Shaw JF, Budiansky D, Sharif F, McIsaac DI. The association of frailty with outcomes after cancer surgery: a systematic review and metaanalysis. Ann Surg Oncol. 2022;29(8):4690–4704.PubMedCrossRef
54.
Shinall MC Jr, Arya S, Youk A, et al. Association of preoperative patient frailty and operative stress with postoperative mortality. JAMA Surg. 2020;155(1):e194620.PubMedCrossRef
55.
Kennedy CA, Shipway D, Barry K. Frailty and emergency abdominal surgery: a systematic review and meta-analysis. Surgeon. 2022;20(6):e307–e314.PubMedCrossRef
56.
Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3(7):e323–e332.PubMedPubMedCentralCrossRef
57.
Mintziras I, Miligkos M, Wächter S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: systematic review and meta-analysis. Int J Surg. 2018;59:19–26.PubMedCrossRef
58.
Rom H, Tamir S, Van Vugt JLA, et al. Sarcopenia as a predictor of survival in patients with pancreatic adenocarcinoma after pancreatectomy. Ann Surg Oncol. 2022;29(3):1553–1563.PubMedCrossRef
59.
Hurst C, Robinson SM, Witham MD, et al. Resistance exercise as a treatment for sarcopenia: Prescription and delivery. Age Ageing 2022;51(2).
60.
Sayer AA, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: Consensus is growing. Age Ageing. 2022;51(10).
Metadata
Title
Prevalence and Impact of Frailty in Pancreatic Cancer: A Systematic Review and Meta-Analysis Based on 35,191 Patients
Authors
Fei Zhang, MD, MPH
Ying Yan, BN
Chunlin Ge, MD
Publication date
29-10-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14426-y

Other articles of this Issue 1/2024

Annals of Surgical Oncology 1/2024 Go to the issue

Gastrointestinal Oncology

Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review

ASO Perspectives

Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?

Pancreatic Tumors

Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma: A Single-Center, Retrospective Study

ASO Visual Abstract

ASO Visual Abstract: Induction of Kallikrein-Related Peptidase 13 and TET2/3 by Anticancer Drugs and the Poor Prognosis for Patients with Esophageal Squamous Cell Carcinoma After Preoperative Treatment

Breast Oncology

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry

Global Health Services Research

Best Practices for Handling Missing Data